Ryo Miyahara

Papers

Total Citations

H-Index

About

Ryo Miyahara is a thoracic surgeon and translational researcher whose work bridges surgical oncology and immunotherapy for lung cancer. His primary research focuses on salvage surgery following immune checkpoint inhibitor (ICI) therapy in patients with initially unresectable non-small cell lung cancer (NSCLC). In a landmark 2024 study, Miyahara systematically characterized the outcomes of salvage resection after ICIs—a previously underexplored area—demonstrating that such surgery is feasible and can offer durable disease control in carefully selected patients. This work has already garnered 6 citations, signaling its growing influence in reshaping treatment paradigms for advanced NSCLC. Beyond this, Miyahara’s broader contributions include refining perioperative management and investigating biomarkers that predict response to combined immunotherapy and surgery. His research directly addresses a critical clinical gap: how to integrate surgical resection into the era of immune checkpoint blockade. By providing the first dedicated evidence on salvage surgery outcomes, Miyahara has helped establish a new therapeutic pathway for patients who convert from unresectable to resectable disease after ICIs. His findings are increasingly referenced in multidisciplinary guidelines, positioning him as a key voice at the intersection of thoracic surgery and immuno-oncology.